From: Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
Beva-cizumab | Year | Entering Interval | Withdrawing during Interval | Exposed to Risk | Terminal Events | Proportion Terminating | Cumulative Proportion Surviving at End of Interval |
---|---|---|---|---|---|---|---|
No | 0–1 | 10,756 | 3050 | 9231 | 517 | .06 | .94 |
1–2 | 7189 | 2336 | 6021 | 327 | .05 | .89 | |
2–3 | 4526 | 1443 | 3805 | 219 | .06 | .84 | |
3–4 | 2864 | 963 | 2383 | 124 | .05 | .80 | |
4–5 | 1777 | 770 | 1392 | 73 | .05 | .76 | |
5–6 | 934 | 611 | 629 | 32 | .05 | .72 | |
6–7 | 291 | 285 | 149 | 6 | .04 | .69 | |
Yes | 0–1 | 5385 | 1527 | 4622 | 470 | .10 | .90 |
1–2 | 3388 | 1099 | 2839 | 238 | .08 | .82 | |
2–3 | 2051 | 631 | 1736 | 168 | .10 | .74 | |
3–4 | 1252 | 407 | 1049 | 99 | .09 | .67 | |
4–5 | 746 | 313 | 590 | 63 | .11 | .60 | |
5–6 | 370 | 249 | 246 | 21 | .09 | .55 | |
6–7 | 100 | 96 | 52 | 4 | .08 | .51 |